Publications by authors named "Cristina Fiamenghi"
Article Synopsis
- Up to 30% of chronic myeloid leukemia (CML) patients may need a treatment change due to issues with first-line tyrosine kinase inhibitors (TKIs), and bosutinib (BOS) emerges as an effective and safe alternative.
- A study analyzed 132 CML patients treated with BOS across 18 hematology centers, finding that most patients switched due to intolerance to previous TKIs, with a significant number achieving positive treatment outcomes.
- The findings suggest that BOS is a preferred treatment choice, particularly for patients who cannot tolerate previous TKIs, demonstrating its safety and effectiveness in real-life settings.
The aim of supportive autografting is to reduce the side effects from stem cell transplantation and avoid procedure-related health disadvantages for patients at the lowest possible cost and resource expenditure. Economic evaluation of health care is becoming increasingly important. We report clinical and laboratory data collected from 397 consecutive adult patients (173 non-Hodgkin lymphoma, 30 Hodgkin lymphoma, 160 multiple myeloma, 7 autoimmune diseases, and 28 acute leukemia) who underwent their first autologous peripheral blood stem cell transplantation (PBSCT).
View Article and Find Full Text PDF